Prospective trial of minimal residual disease assessment by multiparametric flow cytometry for multiple myeloma in the era of bortezomib-based chemotherapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2018-12, Vol.53 (12), p.1589-1592
Hauptverfasser:	Clark, C. Amos, Mosse, Claudio A., Chen, Heidi, Byrne, Michael, Chinratanalab, Wichai, Engelhardt, Brian G., Goodman, Stacey A., Harrell, Shelton L., Kassim, Adetola A., Savani, Bipin N., Sengsayadeth, Salyka, Jagasia, Madan, Cornell, R. Frank
Format:	Artikel
Sprache:	eng
Schlagworte:	13/100 13/31 692/700/1750/1976 692/700/565/2319 Antineoplastic agents Biometry Bortezomib Cancer treatment Cell Biology Chemotherapy Correspondence Development and progression Drug therapy Flow cytometry Hematology Internal Medicine Medical centers Medicine Medicine & Public Health Methods Minimal residual disease Multiple myeloma Patient outcomes Public Health Stem Cells Universities and colleges
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!